Informing MS patients on treatment options: a consensus on the process of consent taking
Authors:
- on behalf of the RIReMS GroupOGon behalf of the RIReMS Group
- C. TortorellaCTC. Tortorella
- M. CalabreseM. Calabrese
- 2 April 2020
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 41 (8) , 2249-2253
Abstract
In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient’s empowerment in the decision-making process. Aims The aims of our project were to review the strategies used by Italian MS specialists to inform patients about treatment options and to design a multicentre shared document that homogenizes the information about disease-modifying treatment (DMTs) and the procedure of taking informed consent in clinical practice. Results The new resource, obtained by consensus among 31 neurologists from 27 MS Centres in Italy with the supervision of a medico-legal advisor, received the aegis of Italian Neurological Society (SIN) and constitutes a step toward a standardized decision process around DMTs in MS.Keywords
This publication has 7 references indexed in Scilit:
- Shared decision-making in multiple sclerosisMultiple Sclerosis Journal, 2016
- The New Era of Informed ConsentJAMA, 2016
- What do multiple sclerosis patients and their caregivers perceive as unmet needs?BMC Neurology, 2013
- Informed consent for clinical treatment: Figure 1:Canadian Medical Association Journal, 2012
- Decisions on multiple sclerosis immunotherapy: New treatment complexities urge patient engagementJournal of the Neurological Sciences, 2011
- Informed shared decision making in multiple sclerosis—inevitable or impossible?Journal of the Neurological Sciences, 2007
- What people with multiple sclerosis perceive to be important to meeting their needsJournal of Advanced Nursing, 2007